New Device Promises Better Pain Readings in Surgery
Published Date: 6/1/2026
Rule
Summary
The FDA is officially putting the adjunctive pain measurement device for anesthesiology into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get new, helpful technology. The new classification is effective June 1, 2026, and could speed up innovation without extra costs for makers.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
New Special Controls Require Validation
Manufacturers must meet specific special controls before marketing: provide clinical data validating algorithms (including accuracy vs a reference, data representativeness, evaluation of pain types, and separate validation datasets for machine-learning algorithms), perform software verification/validation and hazard analysis, non-clinical performance testing for signal quality, usability assessment, biocompatibility testing, and electrical/electromagnetic safety testing.
Adjunctive Pain Device Moved to Class II
The FDA classified the adjunctive pain measurement device for anesthesiology as Class II (special controls), effective June 1, 2026 (classification was applicable February 17, 2023). The device is subject to premarket notification (510(k)) and can serve as a predicate for future devices, which the FDA says reduces regulatory burdens and can speed innovation without imposing extra costs on makers.
Labeling Must Show Clinical Demographics
Labeling for these devices must include a summary of clinical validation data with participant demographics (age, sex, race or ethnicity, patient condition), anesthetic regimen (types and doses), summary of results, information on subpopulations that may have disparate performance, a description of what the device measures and outputs, compatible sensor types, warnings about sensor and patient-condition limitations, and recommendations emphasizing adjunctive use.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-10904, Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation
The FDA is officially putting the new swallowed device for constipation into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool innovation by cutting down red tape. The new rules took effect June 1, 2026, and could save companies time and money getting their devices approved.
Next: 2026-10907, Medical Devices; Anesthesiology Devices; Classification of the Real-Time Ultrasound Anatomy Visualization and Labeling Device for Ultrasound Guided Regional Anesthesia
The FDA is officially classifying a new ultrasound device that helps doctors see and label anatomy in real-time during regional anesthesia as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change makes it easier and faster for patients to get access to this helpful technology without compromising safety. The new classification is effective June 1, 2026, and could save time and money for device makers and hospitals.